Skip to main content
Top
Published in: World Journal of Urology 2/2017

01-02-2017 | Original Article

Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry

Authors: Stanley A. Yap, Lindsay M. Yuh, Christopher P. Evans, Marc A. Dall’Era, Rebecca M. Wagenaar, Rosemary Cress, Primo N. Lara Jr.

Published in: World Journal of Urology | Issue 2/2017

Login to get access

Abstract

Purpose

To assess the shifting population-level practice patterns across a 20-year time span in the management of stage I non-seminomatous germ cell tumors (NSGCT).

Methods

Using the California Cancer Registry, we reviewed all patients with stage I NSGCT between 1988 and 2010. We determined their primary treatment and their overall rates across the years. Other analyzed variables included patient age, T stage, socioeconomic status, race, and year of diagnosis. Predictors of treatment were assessed using logistic regression analysis. Predictors of overall and CSS were assessed using Cox proportional hazards models.

Results

Three thousand nine hundred and sixty-one patients with stage I NSGCT were identified. The most common treatment was surveillance (48 %), followed by RPLND (26 %) and chemotherapy (24 %). Rates of surveillance increased from 35 % in 1988 to 61 % in 2010; rates of RPLND decreased from 44 % in 1988 to 10 % in 2010. These were significant changes in treatment strategies (p < 0.01). Significant predictors of undergoing surveillance included diagnosis after 2006 (OR 1.52, CI 1.25–1.84) and age at diagnosis >60 years old (OR 1.63, CI 1.19–5.82). With a median follow-up of 96 months, 5-year overall survival rate was 95 %.

Conclusions

Treatment patterns in the management of stage I NSGCT have shifted in the past two decades with an increased utilization of surveillance and concurrent decrease in use of RPLND. Surveillance is now the dominant strategy, potentially reflecting changes in perception of the oncologic safety and morbidity profile of such an approach.
Literature
1.
go back to reference Cullen MH, Stenning SP, Parkinson MC et al (1996) Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14:1106–1113PubMed Cullen MH, Stenning SP, Parkinson MC et al (1996) Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14:1106–1113PubMed
2.
go back to reference Sturgeon JF, Moore MJ, Kakiashvili DM et al (2011) Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital’s experience. Eur Urol 59:556–562CrossRefPubMed Sturgeon JF, Moore MJ, Kakiashvili DM et al (2011) Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital’s experience. Eur Urol 59:556–562CrossRefPubMed
3.
go back to reference Kollmannsberger C, Moore C, Chi KN et al (2010) Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 21:1296–1301CrossRefPubMed Kollmannsberger C, Moore C, Chi KN et al (2010) Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 21:1296–1301CrossRefPubMed
4.
go back to reference Albers P, Albrecht W, Algaba F et al (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68:1054–1068CrossRefPubMed Albers P, Albrecht W, Algaba F et al (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68:1054–1068CrossRefPubMed
5.
go back to reference Heidenreich A, Albers P, Hartmann M et al (2003) Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 169:1710–1714CrossRefPubMed Heidenreich A, Albers P, Hartmann M et al (2003) Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 169:1710–1714CrossRefPubMed
6.
go back to reference Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP (1994) Complications of primary retroperitoneal lymph-node dissection for low-stage testicular cancer. World J Urol 12:139–142CrossRefPubMed Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP (1994) Complications of primary retroperitoneal lymph-node dissection for low-stage testicular cancer. World J Urol 12:139–142CrossRefPubMed
7.
go back to reference Studer UE, Fey MF, Calderoni A, Kraft R, Mazzucchelli L, Sonntag RW (1993) Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur Urol 23:444–449PubMed Studer UE, Fey MF, Calderoni A, Kraft R, Mazzucchelli L, Sonntag RW (1993) Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur Urol 23:444–449PubMed
8.
go back to reference Chevreau C, Mazerolles C, Soulie M et al (2004) Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 46:209–214 (discussion 214-205) CrossRefPubMed Chevreau C, Mazerolles C, Soulie M et al (2004) Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 46:209–214 (discussion 214-205) CrossRefPubMed
9.
go back to reference Tandstad T, Stahl O, Hakansson U et al (2014) One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol 25:2167–2172CrossRefPubMed Tandstad T, Stahl O, Hakansson U et al (2014) One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol 25:2167–2172CrossRefPubMed
10.
go back to reference Bohlen D, Burkhard FC, Mills R, Sonntag RW, Studer UE (2001) Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol 165:441–444CrossRefPubMed Bohlen D, Burkhard FC, Mills R, Sonntag RW, Studer UE (2001) Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol 165:441–444CrossRefPubMed
11.
go back to reference Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis LB (2015) Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 33:3105–3115CrossRefPubMedPubMedCentral Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis LB (2015) Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 33:3105–3115CrossRefPubMedPubMedCentral
12.
go back to reference Hjelle LV, Gundersen PO, Oldenburg J et al (2015) Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study. Anticancer Res 35:1619–1625PubMed Hjelle LV, Gundersen PO, Oldenburg J et al (2015) Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study. Anticancer Res 35:1619–1625PubMed
13.
go back to reference Zuniga A, Kakiashvili D, Jewett MA (2009) Surveillance in stage I nonseminomatous germ cell tumours of the testis. BJU Int 104:1351–1356CrossRefPubMed Zuniga A, Kakiashvili D, Jewett MA (2009) Surveillance in stage I nonseminomatous germ cell tumours of the testis. BJU Int 104:1351–1356CrossRefPubMed
14.
go back to reference Nichols CR, Roth B, Albers P et al (2013) Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol 31:3490–3493CrossRefPubMed Nichols CR, Roth B, Albers P et al (2013) Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol 31:3490–3493CrossRefPubMed
15.
go back to reference Sun M, Abdollah F, Budaus L et al (2011) Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study. Ann Surg Oncol 18:2997–3004CrossRefPubMed Sun M, Abdollah F, Budaus L et al (2011) Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study. Ann Surg Oncol 18:2997–3004CrossRefPubMed
16.
go back to reference Ahmed KA, Wilder RB (2014) Outcomes and treatment patterns as a function of time in stage IS testicular seminoma: a population-based analysis. Cancer Epidemiol 38:124–128CrossRefPubMed Ahmed KA, Wilder RB (2014) Outcomes and treatment patterns as a function of time in stage IS testicular seminoma: a population-based analysis. Cancer Epidemiol 38:124–128CrossRefPubMed
17.
go back to reference Swanson DA (1993) The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors. Semin Urol 11:92–98PubMed Swanson DA (1993) The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors. Semin Urol 11:92–98PubMed
18.
go back to reference Gels ME, Hoekstra HJ, Sleijfer DT et al (1995) Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 13:1188–1194PubMed Gels ME, Hoekstra HJ, Sleijfer DT et al (1995) Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 13:1188–1194PubMed
19.
go back to reference Colls BM, Harvey VJ, Skelton L et al (1992) Results of the surveillance policy of stage I non-seminomatous germ cell testicular tumours. Br J Urol 70:423–428CrossRefPubMed Colls BM, Harvey VJ, Skelton L et al (1992) Results of the surveillance policy of stage I non-seminomatous germ cell testicular tumours. Br J Urol 70:423–428CrossRefPubMed
20.
go back to reference Oliver RT, Ong J, Shamash J et al (2004) Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology. 63:556–561CrossRefPubMed Oliver RT, Ong J, Shamash J et al (2004) Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology. 63:556–561CrossRefPubMed
21.
go back to reference Francis R, Bower M, Brunstrom G et al (2000) Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 36:1925–1932CrossRefPubMed Francis R, Bower M, Brunstrom G et al (2000) Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 36:1925–1932CrossRefPubMed
22.
go back to reference Ernst DS, Brasher P, Venner PM et al (2005) Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. Can J Urol 12:2575–2580PubMed Ernst DS, Brasher P, Venner PM et al (2005) Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. Can J Urol 12:2575–2580PubMed
23.
go back to reference Albers P, Albrecht W, Algaba F et al (2011) EAU guidelines on testicular cancer: 2011 update. Eur Urol 60:304–319CrossRefPubMed Albers P, Albrecht W, Algaba F et al (2011) EAU guidelines on testicular cancer: 2011 update. Eur Urol 60:304–319CrossRefPubMed
24.
go back to reference NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. NCCN.org. 2014;version 1.2014 NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. NCCN.org. 2014;version 1.2014
25.
go back to reference Keegan TH, Kurian AW, Gali K et al (2015) Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. Am J Public Health 105:938–946CrossRefPubMedPubMedCentral Keegan TH, Kurian AW, Gali K et al (2015) Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. Am J Public Health 105:938–946CrossRefPubMedPubMedCentral
26.
go back to reference Kish JK, Yu M, Percy-Laurry A, Altekruse SF (2014) Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in surveillance, epidemiology, and end results (SEER) registries. J Natl Cancer Inst Monogr 2014:236–243CrossRefPubMedPubMedCentral Kish JK, Yu M, Percy-Laurry A, Altekruse SF (2014) Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in surveillance, epidemiology, and end results (SEER) registries. J Natl Cancer Inst Monogr 2014:236–243CrossRefPubMedPubMedCentral
Metadata
Title
Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry
Authors
Stanley A. Yap
Lindsay M. Yuh
Christopher P. Evans
Marc A. Dall’Era
Rebecca M. Wagenaar
Rosemary Cress
Primo N. Lara Jr.
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 2/2017
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-016-1870-y

Other articles of this Issue 2/2017

World Journal of Urology 2/2017 Go to the issue